Author

Lawrence Zhu

Howard Hughes Medical InstituteORCID 0000-0002-5070-3076Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Molecular Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

Kevan M. ShokatiD· 2 shared Amalia C. Villagran SuareziD· 1 shared Andrés E. LeschzineriD· 1 shared Delisa RamosiD· 1 shared Elizabeth MoussikhinaiD· 1 shared Erica XiongiD· 1 shared Harry Xiaoying WuiD· 1 shared Janet IwasaiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Kevan M. ShokatORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Chemical Genetic Targeting of the LRRK2 GTPase Domain

Rachel Prorok, Lawrence Zhu, Vickie Bowcut, Harry Xiaoying Wu, Keelan Z. Guiley, Johannes Morstein, Kevan M. Shokat

This study explores targeting the LRRK2 GTPase domain as an alternative to kinase inhibitors to reduce kinase activity with less toxicity.

bioRxiv · Sep 7, 2026 · PreprintMolecular Biology

The structural basis for LRRK2's activation and autoinhibition

Amalia C. Villagran Suarez, Kathryn S. Hatch, Tatyana Bodrug, Wei Gai, Katherine J. Surridge, Elizabeth Moussikhina, Kendrick H V Nguyen, Marta M. Sanz Murillo, Robert Callahan, Erica Xiong, Delisa Ramos, Lawrence Zhu, Verena Dederer, Sebastian Mathea, Janet Iwasa, , Andrés E. Leschziner

This paper elucidates the structural mechanisms by which LRRK2 is activated and autoinhibited, showing how mutations affect these processes and suggesting therapeutic strategies.

Cell · Aug 10, 2026Peer-reviewedNeuroscience